Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $21.4 million.

  • Vanda Pharmaceuticals' Cash from Investing Activities rose 7717.51% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.0 million, marking a year-over-year increase of 18279.45%. This contributed to the annual value of -$17.4 million for FY2024, which is 4457.53% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Cash from Investing Activities stood at $21.4 million, which was up 7717.51% from -$15.3 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $187.3 million during Q1 2023, with a 5-year trough of -$190.9 million in Q2 2023.
  • Its 5-year average for Cash from Investing Activities is -$329631.6, with a median of -$14.6 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 135113.47% in 2021, then skyrocketed by 1520422.54% in 2022.
  • Over the past 5 years, Vanda Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$26.0 million in 2021, then soared by 390.13% to $75.4 million in 2022, then tumbled by 158.05% to -$43.8 million in 2023, then skyrocketed by 109.12% to $4.0 million in 2024, then surged by 434.99% to $21.4 million in 2025.
  • Its last three reported values are $21.4 million in Q3 2025, -$15.3 million for Q2 2025, and $43.9 million during Q1 2025.